Literature DB >> 22249735

IBD: Phase II results for IBD drugs.

Isobel Franks.   

Abstract

Year:  2012        PMID： 22249735     DOI： 10.1038/nrgastro.2011.265

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  2 in total

1.  Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

Authors:  Asit Parikh; Timothy Leach; Tim Wyant; Catherine Scholz; Serap Sankoh; Diane R Mould; Terry Ponich; Irving Fox; Brian G Feagan
Journal:  Inflamm Bowel Dis       Date:  2011-12-06       Impact factor: 5.325

2.  Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.

Authors:  Cosimo Prantera; Herbert Lochs; Maria Grimaldi; Silvio Danese; Maria Lia Scribano; Paolo Gionchetti
Journal:  Gastroenterology       Date:  2011-12-06       Impact factor: 22.682
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.